Cabotegravir + rilpivirine
Cabotegravir + rilpivirine has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Jun 16, 2026: “Long-Acting Cabotegravir/Rilpivirine Reduces Immune-Activation and -Senescence in People With HIV With CMV Co-Infection”.
“Immune-senescence declined in both compartments, with a significant reduction in CD8 senescence at T28, T48 and T72 compared to earlier time-points.”
- 1 lab in 1 country
- Funder: Sapienza University of Rome
- Humans1
What did studies of Cabotegravir + rilpivirine find?
1Studies of Cabotegravir + rilpivirine measured 1 outcome; the most studied are cellular senescence (1 study).
Cellular senescence
downin humans1
1 study
Cellular senescence
downin humans1
Cabotegravir + rilpivirine decreases cellular senescence in humans.
“Immune-senescence declined in both compartments, with a significant reduction in CD8 senescence at T28, T48 and T72 compared to earlier time-points.”
Human trialin people with HIV72 weeksn = 37
Immunology